Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Update


Share on StockTwits

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,140,000 shares, a drop of 16.8% from the March 31st total of 1,370,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

NASDAQ:EGRX traded down $0.72 during midday trading on Tuesday, reaching $41.25. 3,699 shares of the stock traded hands, compared to its average volume of 119,369. The stock has a market capitalization of $545.20 million, a P/E ratio of 118.32 and a beta of 0.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.45 and a current ratio of 3.60. The company has a fifty day moving average of $42.70 and a 200 day moving average of $46.08. Eagle Pharmaceuticals has a 12 month low of $36.48 and a 12 month high of $56.16.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Monday, March 1st. The specialty pharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of ($1.42) by $2.38. Eagle Pharmaceuticals had a net margin of 2.65% and a return on equity of 8.50%. The firm had revenue of $49.92 million during the quarter, compared to the consensus estimate of $50.08 million. On average, analysts predict that Eagle Pharmaceuticals will post -1.07 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Lazard Asset Management LLC boosted its holdings in Eagle Pharmaceuticals by 1,208.9% in the fourth quarter. Lazard Asset Management LLC now owns 1,610 shares of the specialty pharmaceutical company’s stock valued at $74,000 after acquiring an additional 1,487 shares in the last quarter. ProShare Advisors LLC purchased a new stake in Eagle Pharmaceuticals in the fourth quarter worth about $211,000. Oregon Public Employees Retirement Fund grew its holdings in shares of Eagle Pharmaceuticals by 17.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,783 shares of the specialty pharmaceutical company’s stock worth $223,000 after acquiring an additional 724 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at approximately $249,000. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Eagle Pharmaceuticals by 130.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,472 shares of the specialty pharmaceutical company’s stock valued at $255,000 after purchasing an additional 3,098 shares during the period. 95.12% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research raised Eagle Pharmaceuticals from a “sell” rating to a “buy” rating and set a $48.00 target price for the company in a research note on Monday, March 8th.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Read More: Balance Sheet

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.